Actively Recruiting
Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)
Led by Centre Hospitalier Intercommunal Creteil · Updated on 2026-04-08
80
Participants Needed
5
Research Sites
117 weeks
Total Duration
On this page
Sponsors
C
Centre Hospitalier Intercommunal Creteil
Lead Sponsor
F
Ferring Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this study is to evaluate the use of a fixed dose of 3.66 mcg of follitropin delta (Rekovelle) on ovarian response during ovarian stimulation for intrauterine insemination (IUI). The assumption is that this fixed dose will be effective while minimizing the risk of multiple pregnancies. A recent study demonstrated the efficacy of follitropin delta for ovarian stimulation in IUI, and it has been approved in France for controlled ovarian stimulation in assisted reproductive techniques such as in vitro fertilization (IVF) and IVF with intracytoplasmic sperm injection (ICSI). With an adapted dose of Rekovelle for patients with regular menstrual cycles, ovarian stimulation is optimized from the first attempt, promoting the development of two follicles to improve pregnancy chances while reducing the risk of multiple pregnancies. This approach aims to achieve pregnancy faster and provide a more comfortable treatment experience.
CONDITIONS
Official Title
Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Normo-ovulatory patients
- Aged 18 to 38 years old
- Body mass index (BMI) between 18 and 29 kg/m�b2
- Regular menstrual cycles
- At least one healthy Fallopian tube
- Normal uterus cavity
- First treatment for intrauterine insemination (IUI)
- Affiliated with social security
You will not qualify if you...
- Stage III endometriosis
- Total mobile sperm count less than 1 million
- Severe spermatogenesis disorders
- Diagnosis of polycystic ovary syndrome
- History of ovarian hyperstimulation syndrome (OHSS) or excessive response to gonadotrophins
- Chronic diseases contraindicating ovarian stimulation with gonadotrophins
- Known genetic diseases
- Hypothalamus or pituitary tumors
- Ovarian hypertrophy or ovarian cysts not due to polycystic ovary syndrome
- Gynecological bleeding of unknown cause
- Ovarian, uterine, or breast cancer
- Primary ovarian failure
- Genital malformations incompatible with pregnancy
- Uterine fibroids incompatible with pregnancy
- Pregnant women, nursing mothers, persons under guardianship, minors, persons deprived of liberty, or unable to give consent
- Tumors suspected to be progesterone-dependent
- History of liver dysfunction
- Receiving progestogen therapy for more than 6 months
- Known contraindication or adverse events related to hormonal treatments
- Previous thromboembolism events or high risk factors for thromboembolic events
- Previous or current treatment with gonadotrophins
- Hypersensitivity to active substance or excipients
- High risk of OHSS (AMH �b9�b2 35 pmol/L or higher)
- Severe uterine malformation history
- Past ovarian torsion
- Uncontrolled thyroid or adrenal dysfunction
- Hydrosalpinx
- Breast conditions incompatible with gonadotrophin stimulation
- Use of infertility medications affecting follicle stimulation
- Participation in other interventional research
- Unable to understand or sign informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Cabinet Dr Elodie Descat-Polyclinique Jean Villar
Bruges, France, 33520
Actively Recruiting
2
Chi Creteil
Créteil, France, 94000
Actively Recruiting
3
Cabinet Dr Géraldine PORCU-Institut de Médecine de la Reproduction
Marseille, France, 13008
Actively Recruiting
4
Cabinet Dr Nicolas Chevalier-Centre AMP Saint Roch
Montpellier, France, 34070
Actively Recruiting
5
Cabinet Dr Nathalie Massin- Hôpital Américain De Paris
Neuilly-sur-Seine, France, 92200
Suspended
Research Team
A
Aroua Ben Guirat
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here